05 August 2020 | News
The financing brought the total capital raised by the firm to more than $7.5M which will be invested in Gero's proprietary AI/ML platforms for new drugs development for aging and other complicated disorders
Photo Credit: Freepik
Singapore based Biotech Gero has raised $2.2M in Series A round led by Belarus-based Bulba Ventures. Yury Melnichek, the co-founder of Bulba Ventures, has joined Gero's board of directors following the investment.
The financing brought the total capital raised by the firm to more than $7.5M with participation from previous investors and serial entrepreneurs in the fields of pharmaceuticals, IT, and AI. Gero will invest the fund raised to further develop its proprietary AI analytical platform dealing with Clinical and Genetic Data analysis. Gero team aims to find treatment for critical diseases based on age-related genetic analysis. The company plan to invest the fund also in its other ventures such as AI/ML technology necessary for the drug discovery process.
Gero implements massive medical and genetic data from 15-year biobanks of a large population to create a proprietary database of blood samples as part of rejuvenation therapy. Using this data, the platform identifies the adverse proteins that circulate in a populations' blood whose removal or blockage can lead to recovery from a particular disease. These efforts are aimed at healthspan extension and improved quality of life by addressing chronic aging-related diseases, mental disorders, and other health ailments. Gero's AI platform is currently also being utilized to develop COVID-19 drugs to reduce mortality from complications related to ageing.
Additionally, The National University of Singapore has also demonstrated delayed mortality (life-extension) and functional improvements in aged animals after a single experimental treatment. In the future, these new drugs could enable patients to recover after a stroke and could help cancer patients in their fight against accelerated ageing resulting from chemotherapy.